One of the critical path initiatives of the Food and Drug Administration (FDA) is to accelerate the development and availability of a safe and effective artificial pancreas for the treatment of diabetes mellitus. The FDA has established a multidisciplinary group of scientists and clinicians, in partnership with the National Institutes of Health (NIH), to address the clinical, scientific and regulatory challenges related to this unique medical product.:
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ddtec.2007.10.007 | DOI Listing |
Publication Analysis
Top Keywords
artificial pancreas
8
pancreas treatment
8
treatment diabetes
8
diabetes mellitus
8
fda's proactive
4
proactive role
4
role development
4
development artificial
4
mellitus critical
4
critical path
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!